The Conversation (0)
April 29, 2025
INN Article Notification
22 December 2025
Hanlim & Korean Government Fund Pathway to Clinical Trial
Invion Limited (IVX:AU) has announced Hanlim & Korean Government Fund Pathway to Clinical TrialDownload the PDF here. Keep Reading...
02 December 2025
Invion Secures Expanded Photosoft Global Exclusive License
Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
30 October 2025
Appendix 4C and Quarterly Activities Report - September 2025
Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
20 October 2025
Funded Collaboration Agreement with Protect Animal Health
Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
09 October 2025
Repayment of Lind Facility with Successful Capital Raise
Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
23 April
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Contracts signed for Animal Study #2: GLP-1-A26-2Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is... Keep Reading...
21 April
Rewriting the Patient Journey: GLP‑1 Drugs and the Rise of Oral Therapies
Weight loss drugs continue to play out in the global market, with forecasts estimated at a value of US$200 billion by 2030.Leading the rise are oral GLP-1 drugs, with new obesity pills projected to push the GLP-1 market into its next chapter in 2026. The demand is perpendicular to rising obesity... Keep Reading...
21 April
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
600,000 New Wegovy® Pill Prescriptions Written in First Two Months KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the... Keep Reading...
15 April
Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness
Triple ISO Certification Recognition Positions Company as a Standard-Bearer in Clinical Decision Support Quality Infrastructure
Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that Seegnal eHealth Ltd., its Israeli operating subsidiary, has been granted the prestigious Gold Mark by the... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00